This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why
by Zacks Equity Research
Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.
Why Earnings Season Could Be Great for argenx (ARGX)
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Sundeep Ganoria
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
argenex SE (ARGX) Upgraded to Buy: Here's Why
by Zacks Equity Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and argenex SE (ARGX) have performed compared to their sector so far this year.
Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Here's Why argenex SE (ARGX) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does argenex SE (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Immunovant (IMVT) Focus on Developing Autoimmune Disease Drug
by Zacks Equity Research
Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.
Best Momentum Stocks to Buy for August 3rd
by Zacks Equity Research
SSB, XOM and ARGX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 3, 2022.
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
by Zacks Equity Research
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
by Zacks Equity Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
by Zacks Equity Research
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
by Zacks Equity Research
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
Should You Buy argenx SE (ARGX) Ahead of Earnings?
by Zacks Equity Research
argenx SE (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Materialise (MTLS) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Materialise's (MTLS) fourth-quarter 2021 earnings are likely to have benefited from solid operational performance in all three segments.
Splunk (SPLK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Splunk's (SPLK) fourth-quarter fiscal 2022 performance is likely to have benefited from solid demand for cloud-based solutions and customer additions.
SEMrush (SEMR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
SEMrush's (SEMR) fourth-quarter 2021 performance is likely to have benefited from growth in user licenses per customer along with strength in product add-ons.
Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
by Zacks Equity Research
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.